Johnson Investment Counsel Inc. Has $3.94 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Johnson Investment Counsel Inc. decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 7,920 shares of the medical research company's stock after selling 1,111 shares during the period. Johnson Investment Counsel Inc.'s holdings in Thermo Fisher Scientific were worth $3,941,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Cypress Advisory Group LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $253,000. Intact Investment Management Inc. boosted its position in shares of Thermo Fisher Scientific by 34.0% in the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock valued at $1,353,000 after acquiring an additional 660 shares during the period. Purkiss Capital Advisors LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth about $1,121,000. LaFleur & Godfrey LLC boosted its holdings in Thermo Fisher Scientific by 9.1% in the 4th quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company's stock valued at $15,486,000 after purchasing an additional 2,488 shares during the period. Finally, Deutsche Bank AG increased its holdings in shares of Thermo Fisher Scientific by 9.5% during the fourth quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock worth $687,553,000 after purchasing an additional 114,277 shares during the period. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Up 1.2%

Shares of NYSE:TMO traded up $4.75 during midday trading on Friday, hitting $397.31. 3,760,318 shares of the stock were exchanged, compared to its average volume of 1,952,226. The business's 50-day moving average price is $413.43 and its 200 day moving average price is $488.79. The stock has a market capitalization of $149.98 billion, a price-to-earnings ratio of 23.30, a P/E/G ratio of 2.07 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The company's revenue was up .2% on a year-over-year basis. During the same period in the prior year, the company posted $5.11 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Analysts Set New Price Targets

TMO has been the topic of a number of analyst reports. Robert W. Baird reduced their price target on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Stifel Nicolaus reduced their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Royal Bank Of Canada dropped their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Barclays decreased their target price on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Finally, Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $605.30.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.